Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review.

"Conflict of Interest Statement Arndt Vogel: speaker, consultancy, and advisory fees from AstraZeneca, Bayer, BMS, BTG, Daiichi-Sankyo, EISAI, GSK, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Lilly, Merck, MSD, Novartis, PierreFabre, Roche, Sanofi, Servier, Sirtex, and Terumo. R. Katie Kelley: consulting fees (to institution) from Agios, AstraZeneca, BMS, and Merck; consulting fees (to self) from Exact Sciences, Genentech/Roche, Gilead, and Kinnate; travel support to satellite symposium from Ipsen; and research support (to institution) from Agios, AstraZeneca, Bayer, BMS, Eli Lilly, EMD Serono, Exelixis, Genentech/Roche, LOXO oncology, Merck, Novartis, Partner Therapeutics, Relay Therapeutics, Surface Oncology, and Taiho. Philip Johnson: no conflicts of interest to disclose. Philippe Merle: advisory board fees from AstraZeneca, Bayer, Eisai, Lilly, Merck, and Roche and grants and advisory board fees from Genosciences and Ipsen. Thomas Yau: consulting or advisory fees and honoraria from AbbVie, AstraZeneca, Bayer, BMS, Eisai, Eli Lilly, EMD Serono, Exelixis, H3 Biomedicine, Ipsen, Merck Sharp & Dohme Corp., Novartis, New B Innovation, OrigiMed, Pfizer, SillaJen, Sirtex, and Taiho. Masatoshi Kudo: honoraria and consulting or advisory fees from Bayer AG and Eisai Co. Ltd.; honoraria from Bayer AG, Bristol Myers Squibb, EA Pharma, Eisai, and Merck Sharp & Dohme; and research funding from Bayer, Chugai Pharmaceutical, Daiichi-Sankyo, Merck Sharp & Dohme, Ono Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, and Taiho Pharmaceutical. Tim Meyer: consulting fees from Adaptimmune, AstraZeneca, BMS, Boston Scientific, Eisai, Ipsen, and Roche. Lorenza Rimassai: consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Servier, Taiho Oncology, and Zymeworks; lecture fees from AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, and Sanofi; travel expenses from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, and Zymeworks."

"This study was funded by Ipsen. TM is supported by the NIHR UCLH Biomedical Research Centre."

"The protocol for this systematic literature review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration number CRD42021244588) []. The review was conducted in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [, ]. Methods: This was a PRISMA-standard review and was registered with PROSPERO (CRD42021244588). MEDLINE and Embase were systematically searched (March 24, 2021) to identify publications reporting the efficacy and/or safety of systemic anticancer therapy (vs. any/no comparator) in liver-function-defined subgroups in phase 2 or 3 aHCC trials. Screening was completed by a single reviewer, with uncertainties resolved by a second reviewer and/or the authors. English-language full-text articles and congress abstracts were eligible for inclusion. Included publications were described and assessed for risk of bias using the GRADE methodology."